Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (Rapid Reviews Infectious Diseases)
Abstract
Autoantibodies have been shown to be implied in COVID-19 but the emerging autoantibody repertoire remains largely unexplored. We investigated the new-onset autoantibody repertoire in 525 healthcare workers and hospitalized COVID-19 patients in five time points over 16 months using proteome-wide and targeted protein and peptide arrays. Our results show that prevalent new-onset autoantibodies against a wide range of antigens emerged following SARS-CoV-2 infection in relation to pre-infectious baseline samples and remained elevated for at least 12 months. We demonstrated associations between distinct new-onset autoantibodies and neuropsychiatric symptoms post-COVID-19. Using epitope mapping, we determined the main epitopes of selected new-onset autoantibodies, validated them in independent cohorts of neuro-COVID and pre-pandemic healthy controls, and identified molecular mimicry between main epitopes and the conserved fusion peptide of the SARS-CoV-2 Spike glycoprotein. Our work describes the complexity and dynamics of the autoantibody repertoire emerging with COVID-19 and supports the need for continued analysis of the new-onset autoantibody repertoire to elucidate the mechanisms of the post-COVID-19 condition.
Article activity feed
-
Siddharth Sridhar, James Yiu-Hung Tsoi
Review 3: "Prevalent and Persistent New-Onset Autoantibodies in Mild to Severe COVID-19"
The findings suggest that novel autoantibodies identified in the study may serve as important biomarkers for predicting the onset and persistence of autoimmune diseases in individuals affected by COVID-19.
-
Marvin J Fritzler
Review 2: "Prevalent and Persistent New-Onset Autoantibodies in Mild to Severe COVID-19"
The findings suggest that novel autoantibodies identified in the study may serve as important biomarkers for predicting the onset and persistence of autoimmune diseases in individuals affected by COVID-19.
-
Terry O Harville
Review 1: "Prevalent and Persistent New-Onset Autoantibodies in Mild to Severe COVID-19"
The findings suggest that novel autoantibodies identified in the study may serve as important biomarkers for predicting the onset and persistence of autoimmune diseases in individuals affected by COVID-19.
-
Strength of evidence
Reviewers: T O Harville (University of Arkansas) | 📒📒📒 ◻️◻️
M J Fritzler (University of Calgary) | 📒📒📒◻️◻️
S Sridhar & J Y Tsoi(University of Hong Kong) | 📒📒📒◻️◻️ -
